

Ag1 ADC efficacy in the A2058 melanoma xenograft model
untreated
Ag1-MC-VC-Ag1-MMAE
Ag1-Ex. 61
Ag1-Ex. 60
Ag1-Ex. 77
Ag1-Ex. 78
Ag1-Ex. 79
Ag1-Ex. 80
Tumor Volume (mm3)
0
200
400
600
800
0
10
20
30
40
Days Post Implant

FIG. 1



h2A2 ADC efficacy in the Detroit 562-39 pharyngeal xenograft model
Tumor Volume (mm³)
1000
800
600
400
200
0
0
10
20
30
40
50
Days Post Implant
KD0
untreated
h2A2-MC-VC-MMAE
h2A2-Ex. 61
h2A2-Ex. 59
h2A2-Ex. 60
h2A2-Ex. 77
h2A2-Ex. 78
h2A2-Ex. 79
h2A2-Ex. 80

FIG. 2



cAC10 ADC efficacy in the Karpas/KarpasBVR
Hodgkin lymphoma xenograft model
untreated
cAC10-MC-VC-MMAE
cAC10-MC-VC-MMAF
cAC10-Ex. 69
cAC10-Ex. 61
Tumor Volume (mm3)
0
500
1000
0
10
20
30
40
Days Post Implant

FIG. 3



cAC10 ADC efficacy in the Karpas Hodgkin lymphoma xenograft model
untreated
cAC10-MC-VC-MMAE
cAC10-61
cAC10-49
Tumor Volume (mm³)
1500
1000
500
0
0
10
20
30
40
50
Days Post Implant

FIG. 4



ADC efficacy in a Hodgkin Lymphoma xenograft
untreated
cAC10-MC-VC-MMAE
cAC10-Ex. 60
cAC10-Ex. 58
Tumor Volume (mm3)
1500
1000
500
0
0
10
20
30
40
50
Days Post Implant

FIG. 5



Neutrophils (Day 5 and 8)
Neutrophils per uL (10^3)
0
2
4
Untreated D5
(0 mg) D8
MC-VC-MMAE D5
(15 mg/kg) D8
Example 61 D5
(80 mg/kg) D8
Example 59 D5
(80 mg/kg) D8
Example 60 D5
(80 mg/kg) D8
Example 77 D5
(80 mg/kg) D8
Example 79 (80 mg/kg) D5
Example 80 D5
(80 mg/kg) D8
Example 71 D5
(80 mg/kg) D8
Example 70 D5
(80 mg/kg) D8
Example 72 D5
(80 mg/kg) D8

FIG. 6



Reticulocytes (Day 5 and 8)
Reticulocytes per uL (10^3)
0
200
400
Untreated D5
(0 mg) D8
MC-VC-MMAE D5
(15 mg/kg) D8
KD0?-VC-MMAF D5
mg/kg) D8
Example 61 D5
(80 mg/kg) D8
Example 59 D5
(80 mg/kg) D8
Example 60 D5
(80 mg/kg) D8
Example 77 D5
(80 mg/kg) D8
Example 79 D5
(80 mg/kg) D8
Example 80 D5
(80 mg/kg) D8
Example 71 D5
(80 mg/kg) D8
Example 70 D5
(80 mg/kg) D8
Example 72 D5
(80 mg/kg) D8

FIG. 7



Platelets (Day 5 and 8)
Platelets per uL (10^3)
2500
2000
1500
1000
500
0
Untreated D5
(0 mg) D8
MC-VC-MMAE D5
(15 mg/kg) D8
MC-VC-MMAF D5
(15 mg/kg) D8
Example 61 D5
(80 mg/kg) D8
Example 59 D5
(80 mg/kg) D8
Example 60 D5
(80 mg/kg) D8
Example 77 D5
(80 mg/kg) D8
Example 79 (80 mg/kg) D5
Example 80 D5
(80 mg/kg) D8
Example 71 D5
(80 mg/kg) D8
Example 70 D5
(80 mg/kg) D8
Example 72 D5
(80 mg/kg) D8

FIG. 8



AST (day 8)
AST (U/L)
800
600
400
200
0
0 mg/kg (Untreated)
15 mg/kg MC-VC-MMAE
15 mg/kg MC-VC-MMAF
80 mg/kg Example 59
80 mg/kg Example 61
80 mg/kg Example 60
80 mg/kg Example 78
80 mg/kg Example 77
80 mg/kg Example 80

FIG. 9



hCR011 ADC efficacy in the WM2664 xenograft model
Untreated
3 mg/kg Non-binding-Ex. 60
3 mg/kg hCR011-MC-VC-MMAE
3 mg/kg hCR011-Ex. 60
9 mg/kg hCR011-Ex. 60
Dosing schedule: Q1Wx3
4/5 CR
Mean Tumor Volume ± SD (mm3)
1200
900
600
300
0
10
20
30
40
50
60
70
Days Post Implant

FIG. 10



hCR011 ADC efficacy in the SKMEL5 xenograft model
Mean Tumor Volume ± SD (mm³)
1200
900
600
300
0
20
30
40
50
60
70
Days Post Implant
Untreated
3 mg/kg Non-binding-MC-VC-MMAE
9 mg/kg Non-binding-Ex. 60
3 mg/kg hCR011-MC-VC-MMAE
3 mg/kg hCR011-Ex. 60
9 mg/kg hCR011-Ex. 60
Dosing schedule: Q1Wx3

FIG. 11



hCR011 and Ag2 ADC efficacy in the PDX_1 model of Melanoma
Mean Tumor Volume ± SD (mm3)
2000
1500
1000
500
0
0
5
10
15
20
25
30
Days Post Dose
Vehicle
3 mg/kg Non-binding-MC-VC-MMAE
9 mg/kg Non-binding-Ex. 60
3 mg/kg Ag2-MC-VC-MMAE
9 mg/kg Ag2-Ex. 60
3 mg/kg hCR011-MC-VC-MMAE
3 mg/kg hCR011-Ex. 60
9 mg/kg hCR011-Ex. 60
Dosing schedule: Q1Wx3

FIG. 12



hCR011 and Ag2 ADC efficacy in the PDX_4 model of Melanoma
Mean Tumor Volume ± SD (mm³)
2500
2000
1500
1000
500
0
0
5
10
15
20
25
30
Days Post Dose
Vehicle
3 mg/kg Non-binding-MC-VC-MMAE
9 mg/kg Non-binding-Ex. 60
3 mg/kg Ag2-MC-VC-MMAE
9 mg/kg Ag2-Ex. 60
3 mg/kg hCR011-MC-VC-MMAE
3 mg/kg hCR011-Ex. 60
9 mg/kg hCR011-Ex. 60
Dosing schedule: Q1Wx3

FIG. 13



hCR011 and Ag2 ADC efficacy in the PDX_3 model of NSCLC
Vehicle
3 mg/kg Non-binding-MC-VC-MMAE
9 mg/kg Non-binding-Ex. 60
3 mg/kg Ag2-MC-VC-MMAE
9 mg/kg Ag2-Ex. 60
3 mg/kg hCR011-MC-VC-MMAE
3 mg/kg hCR011-Ex. 60
9 mg/kg hCR011-Ex. 60
Dose schedule: Q1Wx3
Mean Tumor Volume ± SD (mm3)
3000
2500
2000
1500
1000
500
0
0
5
10
15
20
25
30
Days Post Dose

FIG. 14



hCR011 and Ag2 ADC efficacy in the PDX_2 model of NSCLC
Mean Tumor Volume ± SD (mm³)
2500
2000
1500
1000
500
0
0
10
20
30
40
50
60
Days Post Dose
Vehicle
3 mg/kg Non-binding-MC-VC-MMAE
9 mg/kg Non-binding-Ex. 60
3 mg/kg Ag2-MC-VC-MMAE
9 mg/kg Ag2-Ex. 60
3 mg/kg hCR011-MC-VC-MMAE
3 mg/kg hCR011-Ex. 60
9 mg/kg hCR011-Ex. 60
Dose Schedule: Q1Wx3

FIG. 15



PDX_1
PDX_2
PDX_3
PDX_4
SKMEL5
WM2664
AUC.3
0.15
0.10
0.05
0.00
-0.05
-0.10
Untreated
3 mg/kg MC-VC-MMAE
3 mg/kg Ex. 60
9 mg/kg Ex. 60
hCR011-ADCs

FIG. 16



Neutrophils (Baseline, Day 8, 15 and 29)
Neutrophils per uL (10^3)
0
2
4
6
8
MC-VC-MMAE
(3 mg/kg)
BL
D8
D15
D29
Example 60
(5 mg/kg)
BL
D8
D15
D29
Example 60
(10 mg/kg)
BL
D8
D15
D29

FIG. 17



Reticulocytes (Baseline, Day 8, 15 and 29)
Reticulocytes per uL (10^3)
200
150
100
50
0
MC-VC-MMAE
(3 mg/kg)
Example 60
(5 mg/kg)
Example 60
(10 mg/kg)
BL
D8
D15
D29

FIG. 18



Platelets (Baseline, Day 8, 15 and 29)
Platelets per uL (10^3)
800
700
600
500
400
300
MC-VC-MMAE
BL
(3 mg/kg)
D8
D15
D29
Example 60
BL
(5 mg/kg)
D8
D15
D29
Example 60
BL
(10 mg/kg)
D8
D15
D29

FIG. 19



AST (Baseline and Day 8)
AST (U/L)
150
100
50
0
MC-VC-MMAE
BL
D8
(3 mg/kg)
Example 60
BL
D8
(5 mg/kg)
Example 60
BL
D8
(10 mg/kg)

FIG. 20



Neutrophils (Baseline and Day 8)
8
6
4
2
0
hCR011-MC-VC-MMAE 5 mg/kg baseline
hCR011-MC-VC-MMAE 5 mg/kg D8
hCR011-Ex. 60 5 mg/kg baseline
hCR011-Ex. 60 5 mg/kg D8

FIG. 21